Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Health Sciences profile

Professor Murray Barclay

PositionClinical Professor
DepartmentDepartment of Medicine (UOC)
QualificationsMB ChB MD(Otago) FRACP
Research summaryGastroenterology/ clinical pharmacology

Research

Murray Barclay is a Clinical Pharmacologist half-time, a Gastroenterologist half-time, and Clinical Professor with the University of Otago. His research interests include inflammatory bowel disease genetics and pharmacogenetics, medicines in gastroenterology, and drug concentration monitoring. He runs clinical trials of new medicines in gastroenterology and has an interest in web-based interactive teaching in medicine.

Publications

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2017). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 73, 71-78. doi: 10.1007/s00228-016-2133-y

Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., … IBD Sydney Organisation, and the Australian Inflammatory Bowel Diseases Consensus Working Group. (2017). Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics, 46, 1037-1053. doi: 10.1111/apt.14368

Kannangara, D. R. W., Graham, G. G., Wright, D. F. B., Stocker, S. L., Portek, I., Pile, K. D., Barclay, M. L., … Stamp, L. K., & Day, R. O. (2017). Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology. Advance online publication. doi: 10.1111/bcp.13307

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6 mg/dL: An open-label extension study. Annals of the Rheumatic Diseases. Advance online publication. doi: 10.1136/annrheumdis-2017-211873

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases. Advance online publication. doi: 10.1136/annrheumdis-2016-210872

Edited Book - Other

Begg, E., Barclay, M., Vella-Brincat, J., Gardiner, S. J., Doogue, M., McDermott, L., … Chambers, S., & Murdoch, D. (Eds.). (2004). Preferred Medicines List (8th ed.). Christchurch: The Caxton Press, 172p.

^ Top of page

Chapter in Book - Other

Frizelle, F., & Barclay, M. (2008). Constipation in adults. In C. Young (Ed.), Clinical evidence handbook: The international source of the best available evidence for effective health care. (pp. 167). UK: BMJ: Evidence Centre.

^ Top of page

Journal - Research Article

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2017). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 73, 71-78. doi: 10.1007/s00228-016-2133-y

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases. Advance online publication. doi: 10.1136/annrheumdis-2016-210872

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6 mg/dL: An open-label extension study. Annals of the Rheumatic Diseases. Advance online publication. doi: 10.1136/annrheumdis-2017-211873

Kannangara, D. R. W., Graham, G. G., Wright, D. F. B., Stocker, S. L., Portek, I., Pile, K. D., Barclay, M. L., … Stamp, L. K., & Day, R. O. (2017). Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology. Advance online publication. doi: 10.1111/bcp.13307

Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., … IBD Sydney Organisation, and the Australian Inflammatory Bowel Diseases Consensus Working Group. (2017). Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics, 46, 1037-1053. doi: 10.1111/apt.14368

Chambers, C., Frampton, C., & Barclay, M. (2017). Presenteeism in the New Zealand senior medical workforce: A mixed-methods analysis. New Zealand Medical Journal, 130(1449), 10-21. Retrieved from https://www.nzma.org.nz/journal

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2017). Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models. Journal of Pharmacokinetics & Pharmacodynamics. Advance online publication. doi: 10.1007/s10928-017-9530-4

Huelsen, A., Oumer, R., Ashcroft, A., Roberts, R. H., Coulter, G. N., Kelly, S. J., & Barclay, M. L. (2016). Achalasia: A 13-year, single-centre experience comparing endoscopic balloon dilation and laparoscopic Heller myotomy. New Zealand Medical Journal, 129(1433), 45-54. Retrieved from http://www.nzma.org.nz/journal

Wright, D. F. B., Duffull, S. B., Merriman, T. R., Dalbeth, N., Barclay, M. L., & Stamp, L. K. (2016). Predicting allopurinol response in patients with gout. British Journal of Clinical Pharmacology, 81(2), 277-289. doi: 10.1111/bcp.12799

McCombie, A., Langlotz, T., Barclay, M., Walmsley, R., Regenbrecht, H., & Schultz, M. (2016). Systematic review of IBD smartphone apps for symptom monitoring and communication with healthcare professionals. Journal of mHealth, 3(3), 36-41. Retrieved from http://www.thejournalofmhealth.com/

Chambers, C. N. L., Frampton, C. M. A., Barclay, M., & McKee, M. (2016). Burnout prevalence in New Zealand's public hospital senior medical workforce: A cross-sectional mixed methods study. BMJ Open, 6(11), e013947. doi: 10.1136/bmjopen-2016-013947

Huelsen, A., Fischer, J., Hegarty, J., Ashcroft, A., Frampton, C. M. A., & Barclay, M. L. (2016). The scratch test for identifying the lower liver edge is at least as accurate as percussion and is significantly more effective for young trainees: A randomised comparative trial. New Zealand Medical Journal, 129(1446), 53-63. Retrieved from http://www.nzma.org.nz/journal

Hock, B. D., Stamp, L. K., Hayman, M. W., Keating, P. E., Helms, E. T. J., & Barclay, M. L. (2016). Development of an ELISA-based competitive binding assay for the analysis of drug concentration and anti-drug antibody levels in patients receiving adalimumab or infliximab. Therapeutic Drug Monitoring, 38(1), 32-41. doi: 10.1097/ftd.0000000000000229

Doecke, J. D., Simms, L. A., Zhao, Z. Z., Roberts, R. L., Fowler, E. V., Croft, A., … Barclay, M. L., Merriman, T. R., Gearry, R. B., … Radford-Smith, G. L. (2015). Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease. Journal of Gastroenterology & Hepatology, 30(2), 299-307. doi: 10.1111/jgh.12674

Chua, E. W., Cree, S., Barclay, M. L., Doudney, K., Lehnert, K., Aitchison, A., & Kennedy, M. A. (2015). Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers. Pharmacogenomics Journal, 15, 414-421. doi: 10.1038/tpj.2015.9

Roberts, R. L., & Barclay, M. L. (2015). Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics, 16(8), 891-903. doi: 10.2217/pgs.15.29

Buffery, P. J., Allen, K. M., Chin, P. K. L., Moore, G. A., Barclay, M. L., & Begg, E. J. (2014). Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: Can the strategy be improved? Therapeutic Drug Monitoring, 36(1), 86-92. doi: 10.1097/FTD.0b013e31829dc940

Korell, J., Duffull, S. B., Dalrymple, J. M., Drake, J., Zhang, M., Barclay, M. L., & Stamp, L. K. (2014). Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. British Journal of Clinical Pharmacology, 77(3), 493-497. doi: 10.1111/bcp.12209

Chin, P. K. L., Wright, D. F. B., Zhang, M., Wallace, M. C., Roberts, R. L., Patterson, D. M., Jensen, B. P., Barclay, M. L., & Begg, E. J. (2014). Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs in R&D, 14(2), 113-123. doi: 10.1007/s40268-014-0045-9

Chin, P. K. L., Patterson, D. M., Zhang, M., Jensen, B. P., Wright, D. F. B., Barclay, M. L., & Begg, E. J. (2014). Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. British Journal of Clinical Pharmacology, 78(3), 630-638. doi: 10.1111/bcp.12366

Stamp, L. K., & Barclay, M. (2014). Therapeutic drug monitoring in rheumatic diseases: Utile or futile? Rheumatology, 53(6), 988-997. doi: 10.1093/rheumatology/ket355

Pan, S., Stamp, L. K., Duffull, S. B., Barclay, M. L., Dalrymple, J. M., Drake, J., Zhang, M., & Korell, J. (2014). Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clinical Pharmacokinetics, 53(12), 1161-1170. doi: 10.1007/s40262-014-0179-5

Stamp, L. K., Merriman, T. R., Barclay, M. L., Singh, J. A., Roberts, R. L., Wright, D. F. B., & Dalbeth, N. (2014). Impaired response or insufficient dosage? Examining the potential causes of ”inadequate response” to allopurinol in the treatment of gout. Seminars in Arthritis & Rheumatism, 44(2), 170-174. doi: 10.1016/j.semarthrit.2014.05.007

Falvey, J. D., Bentley, R. W., Merriman, T. R., Hampton, M. B., Barclay, M. L., Gearry, R. B., & Roberts, R. L. (2013). Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis. World Journal of Gastroenterology, 19(39), 6656-6664. doi: 10.3748/wjg.v19.i39.6656

Beaudoin, M., Goyette, P., Boucher, G., Lo, K. S., Rivas, M. A., Stevens, C., … and also Barclay, M., Gearry, R., & Roberts, R. (2013). Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genetics, 9(9), e1003723. doi: 10.1371/journal.pgen.1003723

Van Egmond, R., Barclay, M. L., Chin, P. K. L., Sies, C. W., & Florkowski, C. M. (2013). Biological variation of thiopurine methyltransferase enzyme activity: When has a significant change taken place? Annals of Clinical Biochemistry, 50(5), 473-478. doi: 10.1177/0004563212473441

Chin, P. K. L., Vella-Brincat, J. W. A., Walker, S. L., Barclay, M. L., & Begg, E. J. (2013). Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Internal Medicine Journal, 43(7), 778-783. doi: 10.1111/imj.12170

International Multiple Sclerosis Genetic Consortium (IMSGC), and also Mason, D., Barclay, M., Roberts, R., & Gearry, R. (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 45(11), 1353-1360. doi: 10.1038/ng.2770

Nasir, B. F., Griffiths, L. R., Nasir, A., Roberts, R., Barclay, M., Gearry, R. B., & Lea, R. A. (2013). An envirogenomic signature is associated with risk of IBD-related surgery in a population-based Crohn’s disease cohort. Journal of Gastrointestinal Surgery, 17(9), 1643-1650. doi: 10.1007/s11605-013-2250-1

Korell, J., Stamp, L. K., Barclay, M. L., Dalrymple, J. M., Drake, J., Zhang, M., & Duffull, S. B. (2013). A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clinical Pharmacokinetics, 52(6), 475-485. doi: 10.1007/s40262-013-0052-y

Koning, M., Ailabouni, R., Gearry, R. B., Frampton, C. M. A., & Barclay, M. L. (2013). Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: A population-based, case-control study. Inflammatory Bowel Diseases, 19(4), 767-778. doi: 10.1097/MIB.0b013e31827f27c8

Wright, D. F. B., Stamp, L. K., Merriman, T. R., Barclay, M. L., Duffull, S. B., & Holford, N. H. G. (2013). The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European Journal of Clinical Pharmacology, 69(7), 1411-1421. doi: 10.1007/s00228-013-1478-8

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2013). A simple high-performance liquid chromatography method for simultaneous determination of three triazole antifungals in human plasma. Antimicrobial Agents & Chemotherapy, 57(1), 484-489. doi: 10.1128/aac.00768-12

Nasir, B. F., Griffiths, L., Nasir, A., Roberts, R., Barclay, M., Gearry, R., & Lea, R. A. (2013). Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. Journal of Clinical Gastroenterology, 47(3), 242-245. doi: 10.1097/MCG.0b013e318258314d

Eglinton, T. W., Roberts, R., Pearson, J., Barclay, M., Merriman, T. R., Frizelle, F. A., & Gearry, R. B. (2012). Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort. American Journal of Gastroenterology, 107, 589-596. doi: 10.1038/ajg.2011.437

Zhang, M., Moore, G. A., Fernyhough, L. J., Barclay, M. L., & Begg, E. J. (2012). Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical & Bioanalytical Chemistry, 404(6-7), 2091-2096. doi: 10.1007/s00216-012-6284-0

Eglinton, T. W., Barclay, M. L., Gearry, R. B., & Frizelle, F. A. (2012). The spectrum of perianal Crohn's disease in a population-based cohort. Diseases of the Colon & Rectum, 55(7), 773-777. doi: 10.1097/DCR.0b013e31825228b0

Roberts, R. L., & Barclay, M. L. (2012). Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. Journal of Gastroenterology & Hepatology, 27(10), 1546-1554. doi: 10.1111/j.1440-1746.2012.07220.x

Van Egmond, R., Chin, P., Zhang, M., Sies, C. W., & Barclay, M. L. (2012). High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Alimentary Pharmacology & Therapeutics, 35(10), 1181-1189. doi: 10.1111/j.1365-2036.2012.05084.x

Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P. B., Hui, K. Y., … Gearry, R., … and also Barclay, M., & Roberts, R. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119-124. doi: 10.1038/nature11582

Roberts, R. L., Gallo, L.-M. D., Barclay, M. L., Gómez-García, M., Cardeña, C., Merriman, T. R., Gearry, R. B., & Martin, J. (2012). Independent replication of an association of CNVR7113.6 with Crohn's disease in caucasians. Inflammatory Bowel Diseases, 18(2), 305-311. doi: 10.1002/ibd.21752

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2012). Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: Implications for clinical practice. Rheumatology, 51(9), 1670-1676. doi: 10.1093/rheumatology/kes091

Morgan, A. R., Han, D.-Y., Lam, W.-J., Triggs, C. M., Fraser, A. G., Barclay, M., Gearry, R. B., … Ferguson, L. R. (2011). Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Human Immunology, 72, 1117-1127. doi: 10.1016/j.humimm.2011.08.011

Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., Ross, A. G., Stedman, C. A. M., … Barclay, M. L. (2011). Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology & Hepatology, 26(1), 49-54. doi: 10.1111/j.1440-1746.2010.06489.x

Anderson, C. A., Boucher, G., Lees, C. W., Franke, A., D’Amato, M., Taylor, K. D., … Barclay, M., … Roberts, R., … Gearry, R., … Rioux, J. D. (2011). Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 43(3), 246-254. doi: 10.1038/ng.764

Roberts, R. L., Hollis-Moffatt, J. E., Gómez-García, M., Fransen, K., Ponsioen, C. Y., Crusius, B. A., … Merriman, T. R., Barclay, M. L., Gearry, R. B., & Alizadeh, B. Z. (2011). Association of the protein-tyrosine phosphatase nonreceptor type substrate 1 (PTPNS1) gene with inflammatory bowel disease. Inflammatory Bowel Diseases, 17(2), E19-E21. doi: 10.1002/ibd.21470

Rivas, M. A., Beaudoin, M., Gardet, A., Stevens, C., Sharma, Y., Zhang, C. K., … International Inflammatory Bowel Disease Genetics Consortium, including Barclay, M., Gearry, R., Roberts, R., … Daly, M. J. (2011). Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nature Genetics, 43(11), 1066-1073. doi: 10.1038/ng.952

Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2011). Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including in those with renal impairment. Arthritis & Rheumatism, 63(2), 412-421. doi: 10.1002/art.30119

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Journal of Rheumatology, 38(12), 2540-2547. doi: 10.3899/jrheum.110481

Diaz-Gallo, L.-M., Espino-Paisán, L., Fransen, K., Gómez-García, M., van Sommeren, S., Cardeña, C., … Barclay, M. L., … Gearry, R. B., Roberts, R. L., … Merriman, T. R., … Martin, J. (2011). Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases, 17(11), 2287-2294. doi: 10.1002/ibd.21630

Glubb, D. M., Gearry, R. B., Barclay, M. L., Roberts, R. L., Pearson, J., Keenan, J. I., McKenzie, J., & Bentley, R. W. (2011). NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World Journal of Gastroenterology, 17(23), 2829-2837. doi: 10.3748/wjg.v17.i23.2829

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Relationship between serum urate and plasma oxypurinol in the management of gout: Determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clinical Pharmacology & Therapeutics, 90(3), 392-398. doi: 10.1038/clpt.2011.113

Rossin, E. J., Lage, K., Raychaudhuri, S., Xavier, R. J., Tatar, D., Benita, Y., International Inflammatory Bowel Disease Genetics Constortium, including Roberts, R., Barclay, M., Gearry, R., … Daly, M. J. (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genetics, 7(1), e1001273. doi: 10.1371/journal.pgen.1001273

Stewart, L. C., Day, A. S., Pearson, J., Barclay, M. L., Gearry, R. B., Roberts, R. L., & Bentley, R. W. (2010). SLC11A1 polymorphisms in inflammatory bowel disease and Mycobacterium avium subspecies paratuberculosis status. World Journal of Gastroenterology, 16(45), 5727-5731. doi: 10.3748/wjg.v16.i45.5727

Bentley, R. W., Cleynen, I., Gearry, R. B., Barclay, M. L., Rutgeerts, P., Merriman, T. R., … Roberts, R. L., & Vermeire, S. (2010). Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. Genes & Immunity, 11, 509-514. doi: 10.1038/gene.2010.15

Weersma, R. K., Crusius, J. B. A., Roberts, R. L., Koeleman, B. P. C., Palomino-Morales, R., Wolfkamp, S., Hollis-Moffatt, J. E., … Gearry, R. B., Barclay, M. L., … Merriman, T. R., … Alizadeh, B. Z. (2010). Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations. Inflammatory Bowel Diseases, 16(12), 2080-2089. doi: 10.1002/ibd.21342

Bentley, R. W., Pearson, J., Gearry, R. B., Barclay, M. L., McKinney, C., Merriman, T. R., & Roberts, R. L. (2010). Association of higher DEFB4 genomic copy number with Crohn's disease. American Journal of Gastroenterology, 105(2), 354-359. doi: 10.1038/ajg.2009.582

Triggs, C. M., Munday, K., Hu, R., Fraser, A. G., Gearry, R. B., Barclay, M. L., & Ferguson, L. R. (2010). Dietary factors in chronic inflammation: Food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutation Research: Fundamental & Molecular Mechanisms of Mutagenesis, 690, 123-138. doi: 10.1016/j.mrfmmm.2010.01.020

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., & Barclay, M. L. (2010). Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis & Rheumatism, 62(2), 359-368. doi: 10.1002/art.27201

Simms, L. A., Doecke, J. D., Roberts, R. L., Fowler, E. V., Zhao, Z. Z., McGuckin, M. A., … McCallum, R., … Barclay, M. L., Gearry, R. B., Merriman, T. R., … Radford-Smith, G. L. (2010). KCNN4 gene variant is associated with ileal Crohn's disease in the Australian and New Zealand population. American Journal of Gastroenterology, 105, 2209-2217. doi: 10.1038/ajg.2010.161

Schultz, M., Gearry, R., Walmsley, R., Day, A. S., Fraser, A., Wyeth, J., Barclay, M., … Whiteside, C. (2010). New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease. New Zealand Medical Journal, 123(1314). Retrieved from http://journal.nzma.org.nz/journal/123-1314/4115/content.pdf

Stamp, L. K., Chapman, P. T., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., Kennedy, M. A., & Roberts, R. L. (2010). Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics & Genomics, 20(6), 367-376. doi: 10.1097/FPC.0b013e3283398a71

Ngu, J. H., Bechly, K., Chapman, B. A., Burt, M. J., Barclay, M. L., Gearry, R. B., & Stedman, C. A. M. (2010). Population-based epidemiology study of autoimmune hepatitis: A disease of older women? Journal of Gastroenterology & Hepatology, 25(10), 1681-1686. doi: 10.1111/j.1440-1746.2010.06384.x

Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., … Roberts, R., … Barclay, M., … Gearry, R., … Parkes, M. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 42(12), 1118-1125. doi: 10.1038/ng.717

Roberts, R. L., Topless, R. K. G., Phipps-Green, A. J., Gearry, R. B., Barclay, M. L., & Merriman, T. R. (2010). Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes & Immunity, 11, 351-356. doi: 10.1038/gene.2010.11

Eglinton, T., Reilly, M., Chang, C., Barclay, M., Frizelle, F., & Gearry, R. (2010). Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. British Journal of Surgery, 97(7), 1103-1109. doi: 10.1002/bjs.7031

Gearry, R. B., Richardson, A. K., Frampton, C. M., Dodgshun, A. J., & Barclay, M. L. (2010). Population-based cases control study of inflammatory bowel disease risk factors. Journal of Gastroenterology & Hepatology, 25, 325-333. doi: 10.1111/j.1440-1746.2009.06140.x

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., James, J., & Barclay, M. L. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis & Rheumatism, 60(8), 2248-2256. doi: 10.1002/art.24653

Huebner, C., Ferguson, L. R., Han, D. Y., Philpott, M., Barclay, M. L., Gearry, R. B., & et al (2009). Nucleotide-binding oligomerization domain containing I (NODI) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand Caucasian population: A case-control study. BMC Research Notes, 2, 52. doi: 10.1186/1756-0500-2-52

Petermann, I., Huebner, C., Browning, B. L., Gearry, R. B., Barclay, M. L., Kennedy, M., Roberts, R., … Han, D. Y., & Ferguson, L. R. (2009). Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Human Immunology, 70, 440-446. doi: 10.1016/j.humimm.2009.03.002

Huebner, C., Browning, B. L., Petermann, I., Han, D. Y., Philpott, M., Barclay, M., Gearry, R., … Ferguson, L. R. (2009). Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflammatory Bowel Diseases, 15(12), 1784-1793. doi: 10.1002/ibd.21019

Ferguson, L. R., Han, D. Y., Huebner, C., Petermann, I., Barclay, M. L., Gearry, R. B., … Demmers, P. S. (2009). Tumor necrosis factor receptor superfamily, member 1B haplotypes increase or decrease the risk of inflammatory bowel diseases in a New Zealand Caucasian population. Gastroenterology Research & Practice, 591704. doi: 10.1155/2009/591704

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2009). Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B, 877(27), 3025-3030. doi: 10.1016/j.jchromb.2009.07.021

Petermann, I., Triggs, C. M., Huebner, C., Han, D. Y., Gearry, R. B., Barclay, M. L., … Ferguson, L. R. (2009). Mushroom intolerance: A novel diet-gene interaction in Crohn's disease. British Journal of Nutrition, 102(4), 506-508. doi: 10.1017/s0007114509276446

Browning, B. L., Annese, V., Barclay, M. L., Bingham, S. A., Brand, S., Büning, C., … Gearry, R. B., … Witt, H. (2008). Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. Journal of Medical Genetics, 45(1), 36-42. doi: 10.1136/jmg.2007.050773

Tarrant, K. M., Barclay, M. L., Frampton, C. M. A., & Gearry, R. B. (2008). Perianal disease predicts changes in Crohn's disease phenotype: Results of a population-based study of inflammatory bowel disease phenotype. American Journal of Gastroenterology, 103(12), 3082-3093.

Roberts, R. L., Hollis-Moffatt, J. E., Gearry, R. B., Kennedy, M. A., Barclay, M. L., & Merriman, T. R. (2008). Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes & Immunity, 9(6), 561-565. doi: 10.1038/gene.2008.49

Dalrymple, J. M., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., & Barclay, M. L. (2008). Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism, 58(11), 3299-3308.

Roberts, R. L., Gearry, R. B., Bland, M. V., Sies, C. W., George, P. M., Burt, M., … Barclay, M. L., & Kennedy, M. A. (2008). Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenetics & Genomics, 18(5), 434-438.

Bentley, R. W., Keenan, J. I., Gearry, R. B., Kennedy, M. A., Barclay, M. L., & Roberts, R. L. (2008). Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. American Journal of Gastroenterology, 103(5), 1168-1172. doi: 10.1111/j.1572-0241.2007.01742.x

Gardiner, S. J., Gearry, R. B., Burt, M. J., Ding, S. L., & Barclay, M. L. (2008). Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. European Journal of Gastroenterology & Hepatology, 20(12), 1238-1242. doi: 10.1097/MEG.0b013e3282ffda37

Roberts, R. L., Gearry, R. B., Kennedy, M. A., & Barclay, M. L. (2008). Beyond TPMT: Genetic influences on thiopurine drug responses in inflammatory bowel disease. Personalized Medicine, 5(3), 233-248. doi: 10.2217/17410541.5.3.233

Ferguson, L. R., Huebner, C., Petermann, I., Gearry, R. B., Barclay, M. L., Demmers, P., … Han, D. Y. (2008). Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World Journal of Gastroenterology, 14(29), 4652-4661. doi: 10.3748/wjg.14.4652

Gardiner, S. J., Gearry, R. B., Begg, E. J., Zhang, M., & Barclay, M. L. (2008). Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clinical Gastroenterology & Hepatology, 6(6), 654-660. doi: 10.1016/j.cgh.2008.02.032

Ferguson, L. R., Browning, B. L., Huebner, C., Petermann, I., Shelling, A. N., Demmers, P., … Gearry, R. B., Barclay, M. L., & Philpott, M. (2008). Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population. Digestive & Liver Disease, 40(9), 723-730. doi: 10.1016/j.dld.2008.02.011

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2007). IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics Journal, 7(5), 312-317.

Browning, B. L., Huebner, C., Petermann, I., Gearry, R. B., Barclay, M. L., Shelling, A. N., & Ferguson, L. R. (2007). Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. American Journal of Gastroenterology, 102, 2504-2512.

Roberts, R. L., Gearry, R. B., Hollis-Moffatt, J. E., Miller, A. L., Reid, J., Abkevich, V., … Merriman, T. R., Barclay, M. L., & Kennedy, M. A. (2007). IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. American Journal of Gastroenterology, 102, 2754-2761.

Browning, B. L., Huebner, C., Petermann, I., Demmers, P., McCulloch, A., Gearry, R. B., Barclay, M. L., … Ferguson, L. R. (2007). Association of DLG5 variants with inflammatory bowel disease in the New Zealand caucasian population and meta-analysis of the DLG5 R30Q variant. Inflammatory Bowel Diseases, 13(9), 1069-1076.

Gearry, R. B., Roberts, R. L., Burt, M. J., Frampton, C. M. A., Chapman, B. A., Collett, J. A., Shirley, P., Allington, M. D. E., Kennedy, M. A., & Barclay, M. L. (2007). Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflammatory Bowel Diseases, 13(10), 1220-1227.

Brooks, A. J., Begg, E. J., Zhang, M., Frampton, C. M., & Barclay, M. L. (2007). Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Therapeutic Drug Monitoring, 29(5), 619-625.

Priest, V. L., Begg, E. J., Gardiner, S. J., Frampton, C. M., Gearry, R. B., Barclay, M. L., Clark, D. W., & Hansen, P. (2006). Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics, 24(8), 767-781.

Cameron, R., Barclay, M., & Dobbs, B. (2006). Ambulatory oesophageal manometry and pH monitoring for investigation of chest pain: A New Zealand experience. New Zealand Medical Journal, 119(1230). Retrieved from http://journal.nzma.org.nz/journal/119-1230/1877/content.pdf

Gearry, R. B., Richardson, A., Frampton, C. M., Collett, J. A., Burt, M. J., Chapman, B. A., & Barclay, M. L. (2006). High incidence of Crohn's disease in Canterbury, New Zealand: Results of an epidemiologic study. Inflammatory Bowel Diseases, 12(10), 936-943.

Frizelle, F., & Barclay, M. (2006). Constipation in adults. Clinical Evidence, 15. Retrieved from http://clinicalevidence.bmj.com/ceweb/conditions/dsd/0413/0413.jsp

Gardiner, S. J., Gearry, R. B., Roberts, R. L., Zhang, M., Barclay, M. L., & Begg, E. J. (2006). Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. British Journal of Clinical Pharmacology, 62(4), 453-456.

Gardiner, S. J., Gearry, R. B., Barclay, M. L., & Begg, E. J. (2006). Two cases of thiopurine methyltransferase (TPMT) deficiency: A lucky save and a near miss with azathioprine. British Journal of Clinical Pharmacology, 62(4), 473-476. doi: 10.1111/j.1365-2125.2005.02474.x

Gearry, R., Barclay, M., Florkowski, C., George, P., & Walmsley, T. (2005). Faecal calprotectin: The case for a novel non-invasive way of assessing intestinal inflammation [Viewpoint]. New Zealand Medical Journal, 118(1214). Retrieved from http://journal.nzma.org.nz/journal/118-1214/1444/content.pdf

More publications...